Omega Therapeutics, Inc. filed a combined plan of liquidation with related disclosure statement in the US Bankruptcy Court on May 27, 2025. As per the plan filed, administrative claims, fee claims, U.S. trustee fees, tax claims, other priority claims, and other secured claims shall be paid in full in cash. General unsecured claims shall receive, on the effective date, its pro rata share of the general unsecured claim distribution fund.
Subordinated claims of $0 shall receive no distribution on account of their subordinated claims. Equity interests shall be cancelled and shall receive no distribution pursuant to the plan. The plan shall be funded through cash in hand and asset sale. Omega Therapeutics, Inc. filed a modified combined plan of liquidation with related disclosure statement in the US Bankruptcy Court on June 11, 2025.
As per the plan filed, other priority claims are of $0.33 million, and other secured claims are of $0. General unsecured claims of $7.73 million shall be recovered 32% of $2.47 million. There are no other changes in treatment of any claim class or sources of plan funding. Omega Therapeutics, Inc. filed a solicitation version of modified combined plan of liquidation with related disclosure statement in the US Bankruptcy Court on June 16, 2025.
As per the plan filed, there are no changes in treatment of any claim class or sources of plan funding. Omega Therapeutics, Inc. filed its revised combined plan of liquidation with related disclosure statement in the US Bankruptcy Court on July 28, 2025. As per the plan filed, there are no changes in treatment of any claim class or sources of plan funding.
